Patient characteristics
| Characteristic . | AHSCT recipients without GVHD, n = 22 . | All HSCT recipients with cGVHD, n = 47 . | HSCT recipients with active cGVHD, n = 28 . | HSCT recipients with cGVHD in remission, n = 19 . | P* . |
|---|---|---|---|---|---|
| Male sex, n (%) | 14 (64) | 27 (57) | 15 (54) | 12 (63) | .56 |
| Age at study inclusion, mean (range), y | 41 (19-69) | 47 (20-66) | 47 (26-63) | 46 (20-66) | .89 |
| Time from AHSCT, mean (range), mo | 41 (2-146) | 44 (2-319) | 31 (2-83) | 65 (4-319) | .07 |
| Hematologic disease, n (%) | |||||
| Hodgkin/NHL/CLL/MM | 0/2/3/1 (27) | 4/6/0/4 (30) | 3/5/0/1 (21) | 1/1/0/3 (26) | |
| AML/ALL | 3/2 (23) | 11/8 (40) | 5/3 (32) | 6/5 (56) | |
| MDS/MPS | 3/3 (27) | 8/5 (28) | 7/4 (39) | 1/1 (11) | |
| Aplastic anemia/Hemoglobinopathy | 4/1 (23) | 0/1 (2) | 0/0 | 0/1 (5) | |
| Conditioning: MAC/RIC, n (%) | 1045/12 (55) | 11 (23)/36 (77) | 7 (25)/21 (75) | 4 (21)/15 (79) | |
| Donor type: sibling/MUD, n (%) | 8 (36)/14 (64) | 18 (38)/29 (62) | 11 (39)/17 (61) | 7 (37)/12 (63) | |
| Immunosuppressors at study inclusion, n (%) | 6 (27) | 40 (85) | 22 (79) | 18 (95) | .21 |
| Systemic corticosteroids, n (%) | 1 (5) | 36 (77) | 20 (71) | 16 (84) | .48 |
| Mean dose of steroids (equivalent to prednisone, mg/j) | 20 (0-120) | 24 (0-120) | 13 (0-60) | .41 | |
| Ciclosporin/tacrolimus, n (%) | 5/0 (23) | 15/2 (36) | 11/0 (39) | 4/2 (32) | .76 |
| MMF/MTX, n (%) | 0 | 11/0 (23) | 5 /0 (18) | 6/0 (32) | .31 |
| Rapamycin/everolimus, n (%) | 1 (5) | 1/1 (4) | 1 /0 (4) | 0/ 1 (5) | 1 |
| Extracorporeal photopheresis, n (%) | 0 | 5 (11) | 5 (18) | 0 | .07 |
| Imatinib, n (%) | 0 | 3 (6) | 2 (7) | 1 (5) | 1 |
| cGVHD NIH global severity score, n (%) | NA | ||||
| Mild | 10 (21) | 2 (7) | 8 (42) | .008 | |
| Moderate | 8 (17) | 4 (14) | 4 (21) | .69 | |
| Severe | 29 (62) | 22 (79) | 7 (37) | .006 | |
| cGVHD organ involvement, n (%) | NA | ||||
| Skin | 43 (91) | 24 (86) | 19 (100) | .13 | |
| Lung | 10 (21) | 7 (25) | 3 (16) | .71 | |
| Digestive tract | 15 (32) | 10 (36) | 5 (26) | .54 |
| Characteristic . | AHSCT recipients without GVHD, n = 22 . | All HSCT recipients with cGVHD, n = 47 . | HSCT recipients with active cGVHD, n = 28 . | HSCT recipients with cGVHD in remission, n = 19 . | P* . |
|---|---|---|---|---|---|
| Male sex, n (%) | 14 (64) | 27 (57) | 15 (54) | 12 (63) | .56 |
| Age at study inclusion, mean (range), y | 41 (19-69) | 47 (20-66) | 47 (26-63) | 46 (20-66) | .89 |
| Time from AHSCT, mean (range), mo | 41 (2-146) | 44 (2-319) | 31 (2-83) | 65 (4-319) | .07 |
| Hematologic disease, n (%) | |||||
| Hodgkin/NHL/CLL/MM | 0/2/3/1 (27) | 4/6/0/4 (30) | 3/5/0/1 (21) | 1/1/0/3 (26) | |
| AML/ALL | 3/2 (23) | 11/8 (40) | 5/3 (32) | 6/5 (56) | |
| MDS/MPS | 3/3 (27) | 8/5 (28) | 7/4 (39) | 1/1 (11) | |
| Aplastic anemia/Hemoglobinopathy | 4/1 (23) | 0/1 (2) | 0/0 | 0/1 (5) | |
| Conditioning: MAC/RIC, n (%) | 1045/12 (55) | 11 (23)/36 (77) | 7 (25)/21 (75) | 4 (21)/15 (79) | |
| Donor type: sibling/MUD, n (%) | 8 (36)/14 (64) | 18 (38)/29 (62) | 11 (39)/17 (61) | 7 (37)/12 (63) | |
| Immunosuppressors at study inclusion, n (%) | 6 (27) | 40 (85) | 22 (79) | 18 (95) | .21 |
| Systemic corticosteroids, n (%) | 1 (5) | 36 (77) | 20 (71) | 16 (84) | .48 |
| Mean dose of steroids (equivalent to prednisone, mg/j) | 20 (0-120) | 24 (0-120) | 13 (0-60) | .41 | |
| Ciclosporin/tacrolimus, n (%) | 5/0 (23) | 15/2 (36) | 11/0 (39) | 4/2 (32) | .76 |
| MMF/MTX, n (%) | 0 | 11/0 (23) | 5 /0 (18) | 6/0 (32) | .31 |
| Rapamycin/everolimus, n (%) | 1 (5) | 1/1 (4) | 1 /0 (4) | 0/ 1 (5) | 1 |
| Extracorporeal photopheresis, n (%) | 0 | 5 (11) | 5 (18) | 0 | .07 |
| Imatinib, n (%) | 0 | 3 (6) | 2 (7) | 1 (5) | 1 |
| cGVHD NIH global severity score, n (%) | NA | ||||
| Mild | 10 (21) | 2 (7) | 8 (42) | .008 | |
| Moderate | 8 (17) | 4 (14) | 4 (21) | .69 | |
| Severe | 29 (62) | 22 (79) | 7 (37) | .006 | |
| cGVHD organ involvement, n (%) | NA | ||||
| Skin | 43 (91) | 24 (86) | 19 (100) | .13 | |
| Lung | 10 (21) | 7 (25) | 3 (16) | .71 | |
| Digestive tract | 15 (32) | 10 (36) | 5 (26) | .54 |
AHSCT, allogeneic hematopoietic stem cell transplantation; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; cGVHD, chronic graft-versus-host disease; CLL, chronic lymphocytic leukemia; GVHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplantation; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MM, multiple myeloma; MMF, mycophenolate mofetil; MPS, myeloproliferative syndrome; MTX, methotrexate; MUD, matched unrelated donor; NA, not applicable; NHL, non-Hodgkin lymphoma; NIH, National Institutes of Health; RIC, reduced-intensity conditioning.
Active cGVHD vs remission.